ORENCIA® shows comparable efficacy to Humira®

Bristol-Myers Squibb Company (NYSE: BMY) has announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the safety and efficacy of the subcutaneous (SC) formulation of abatacept versus adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news